Genomic risk in clinic care to promote health equity in New York City patients
Genomic risk in clinic care to promote health equity in New York City patients
批准号:
10850453
负责人:
NOURA SERENE ABUL-HUSN
金额:
$14.97万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-01 至 2025-04-30
关键词:
AdultCaringChildClinicClinicalCommunitiesDataDiseaseElectronic Health RecordElectronic Medical Records and Genomics NetworkEnrollmentEnsureEuropean ancestryFamilyFamily health statusGenesGenetic RiskGenomeGenomic medicineGenomicsGoalsHealthHealth systemIndividualMeasuresMetadataNational Human Genome Research InstituteNew York CityOutcomeParticipantPatientsPhysiciansPredictive ValuePreventivePreventive MedicineProviderRecording of previous eventsReportingResearchResearch PersonnelRiskRisk AssessmentRisk FactorsSiteSurveysTechnologyTestingUnderserved PopulationUnited StatesValidationVariantVisitWorkclinical implementationclinical research sitedisorder riskemerging adulthealth equity promotionhigh riskinstrumentinterestlifestyle factorsmedically underserved populationoutreachpolygenic risk scoreprimary care clinicprospectivepublic health relevancerecruitresponserisk predictionsocialuptakeworking group
中文摘要
整合临床病史、家庭因素的疾病风险预测
英文摘要
PROJECT SUMMARY / ABSTRACT Disease risk prediction that integrates aspects of clinical history, family
history, and lifestyle factors is a core tenet of preventive medicine, with genomic risk increasingly being
recognized as a component that may enhance the prediction of disease. In addition to strong risk factors in single
genes (monogenic risk), polygenic risk scores (PRS) combine the many small effects of variants across the
genome to estimate an individual's disease risk. While PRS are poised to enhance risk prediction for common
disease, current challenges to clinical implementation include lack of validation in non-European ancestry
groups, and barriers to access to leading-edge genomic technology, research, and testing among underserved
populations. The eMERGE 4 Network is conducting a study to prospectively enroll 25,000 adults and children
across 10 clinical sites in the United States and return an integrated risk report, called the Genome Informed
Risk Assessment (GIRA), which incorporates PRS for 10 common conditions with family history, monogenic risk,
social and clinical determinants. Using the GIRA to identify individuals at high risk, the Network will assess uptake
of preventive health measures and health outcomes. The Mount Sinai Health System (MS) has been selected
as an eMERGE 4 enhanced diversity clinical site, where we have recruited 1,520 of our target 2,500 participants,
>75% of whom are from medically underserved populations. At the midpoint of the project, in response to some
delays in Network recruitment, we have been asked to recruit an additional 175 adult participants beyond our
original goal of 2,500. The Specific Aim for this supplement is to expand enrollment of adult participants from
diverse communities in New York City. We will accomplish this by 1) continuing targeted outreach, 2) maintaining
a presence in primary care clinics across Mount Sinai, 3) engaging physician champions, clinic staff, and practice
managers, 4) bringing on additional recruitment sites as needed, 5) extending recruitment through end July 2024,
and 6) continuing outreach and engagement efforts to participants and providers. We will extract data on health
outcomes from electronic health records, and other data as requested. Upon completion of this aim we will
deliver completed surveys, family histories, meta data, and EHR-derived health outcome data for an additional
175 diverse adults from the Mount Sinai Health System to contribute to the research goals of the eMERGE 4
Network, and will work within the eMERGE Network working groups to analyze these data.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1007/s10689-021-00257-x
发表时间:
2022-04
期刊:
Familial cancer
影响因子:
2.2
作者:
[Bar-Mashiah A, Soper ER, Cullina S, Belbin GM, Kenny EE, Lucas AL, Abul-Husn NS]
通讯作者:
Abul-Husn NS
DOI:
10.1200/po.20.00290
发表时间:
2020-01-01
期刊:
JCO precision oncology
影响因子:
4.6
作者:
[Rosenblum, Rachel E, Ang, Celina, Abul-Husn, Noura S]
通讯作者:
Abul-Husn, Noura S
DOI:
10.1016/j.gim.2022.03.006
发表时间:
2022-06
期刊:
GENETICS IN MEDICINE
影响因子:
8.8
作者:
[Suckiel, Sabrina A., Braganza, Giovanna T., Aguiniga, Karla Lopez, Odgis, Jacqueline A., Bonini, Katherine E., Kenny, Eimear E., Hamilton, Jada G., Abul-Husn, Noura S.]
通讯作者:
Abul-Husn, Noura S.
Genomic risk in clinic care to promote health equity in New York City patients
-
批准号:10207725
-
项目类别:
-
资助金额:$186.24万
-
财政年份:2020
-
负责人:NOURA SERENE ABUL-HUSN
-
依托单位:
Genomic risk in clinic care to promote health equity in New York City patients
-
批准号:10657565
-
项目类别:
-
资助金额:$168.74万
-
财政年份:2020
-
负责人:NOURA SERENE ABUL-HUSN
-
依托单位:
Genomic risk in clinic care to promote health equity in New York City patients
-
批准号:10472545
-
项目类别:
-
资助金额:$185.99万
-
财政年份:2020
-
负责人:NOURA SERENE ABUL-HUSN
-
依托单位:
海外基金